Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label recovery failure. Show all posts
Showing posts with label recovery failure. Show all posts

Monday, December 9, 2024

Factors Influencing the Use of Mobile Applications for Driving Rehabilitation After Stroke: Exploring the Perspectives of Occupational Therapists

 No acknowledgement that they are completely failing at getting their patients recovered!

Factors Influencing the Use of Mobile Applications for Driving Rehabilitation After Stroke: Exploring the Perspectives of Occupational Therapists

 
Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days

Abstract

This study describes factors influencing occupational therapists’ implementation of mobile applications into driving rehabilitation post-stroke. A qualitative descriptive design was used to analyze interview data from twenty (n = 20) occupational therapists working in stroke rehabilitation. Key factors include awareness of emerging applications, workplace technology policies, patient impairment levels and technological proficiency, and the involvement of caregivers in patient training. The ability to observe cognitive-perceptual abilities when utilizing mobile applications provided key insights into patient progress. Further investigation is necessary to explore methods for remotely monitoring outcomes in driving rehabilitation.

Thursday, April 28, 2022

Longitudinal Variations of CDC42 in Patients With Acute Ischemic Stroke During 3-Year Period: Correlation With CD4+ T Cells, Disease Severity, and Prognosis

Useless, you're predicting failure to recover using CDC42 levels. What survivor wants to hear that?

Longitudinal Variations of CDC42 in Patients With Acute Ischemic Stroke During 3-Year Period: Correlation With CD4+ T Cells, Disease Severity, and Prognosis

Xiao Cheng1,2, Jianxin Ye3*, Xiaolei Zhang1 and Kun Meng1
  • 1Department of Neurology, ShanXi Province People's Hospital of Shanxi Medical University, Taiyuan, China
  • 2Shanxi Key Laboratory of Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan, China
  • 3Department of Neurology, The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China

Objective: Cell division cycle 42 (CDC42) modulates CD4+ T-cell differentiation, blood lipids, and neuronal apoptosis and is involved in the pathogenesis of acute ischemic stroke (AIS); however, the clinical role of CDC42 in AIS remains unanswered. This study aimed to evaluate the expression of CDC42 in a 3-year follow-up and its correlation with disease severity, T helper (Th)1/2/17 cells, and the prognosis in patients with AIS.

Methods: Blood CDC42 was detected in 143 patients with AIS at multiple time points during the 3-year follow-up period and in 70 controls at admission by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, blood Th1, Th2, and Th17 cells and their secreted cytokines (interferon-γ (IFN-γ), interleukin-4 (IL-4), and interleukin-17A (IL-17A)) in patients with AIS were detected by flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively.

Results: Compared with controls (p < 0.001), CDC42 was reduced in patients with AIS. CDC42 was negatively correlated with the National Institutes of Health Stroke Scale (NIHSS) score (p < 0.001), whereas, in patients with AIS (all p < 0.050), it was positively associated with Th2 cells and IL-4 but negatively correlated with Th17 cells and IL-17A. CDC42 was decreased from admission to 3 days and gradually increased from 3 days to 3 years in patients with AIS (P<0.001). In a 3-year follow-up, 24 patients with AIS recurred and 8 patients died. On the 3rd day, 7th day, 1st month, 3rd month, 6th month, 1st year, 2nd year, and 3rd year, CDC42 was decreased in recurrent patients than that in non-recurrent patients (all p < 0.050). CDC42 at 7 days (p = 0.033) and 3 months (p = 0.023) was declined in reported deceased patients than in survived patients.

Conclusion: CDC42 is used as a biomarker to constantly monitor disease progression and recurrence risk of patients with AIS.

Introduction

Stroke is a common cerebrovascular disease, which has affected nearly 104 million people worldwide in the past three decades and has climbed to the second leading cause of death (second only to ischemic heart disease), besides, stroke is also known for its high disability rate (nearly 33.4–71%) (14). Acute ischemic stroke (AIS) is the primary type of stroke (accounting for ~70% of all stroke cases), which is characterized by immune system disorder, severe neurological deficits, etc. (510). Gradually, diversified therapeutic strategies (including thrombolysis, antiplatelet treatment, anticoagulants, and neuroprotective agents) have been introduced in an attempt to eliminate arterial occlusion, restore blood flow to the brain, and improve the recovery of neurological function; however, AIS is disease prone to recurrence, which requires continuous attention (1116). Therefore, it is imperative to develop objective biomarkers to help identify patients with AIS as soon as possible, predict their outcomes, and then adjust the treatment regimens accordingly.

Cell division cycle 42 (CDC42), a small hydrolase of guanosine triphosphate (GTPase), acts as a signal transduction convergence point that mediates many signaling pathways. Moreover, it is reported that CDC42 regulates blood lipids, blood vessel development, CD4+ T-cell differentiation, microglial process, and neuronal apoptosis in some cardiovascular and cerebrovascular diseases (including ischemic brain injury, coronary heart disease, and cerebrovascular malformations) (1723). For instance, a study found that CDC42 can act as an upstream activator of the c-Jun N-terminal kinase (JNK) signaling pathway to govern neuronal apoptosis in ischemic brain injury (19). Another study explored the correlation between CDC42 and T helper (Th) 2 cells, Th17 cells, and blood lipids in patients with coronary heart disease (20). Interestingly, these CDC42-modulated biological processes (mentioned above) behave as underlying pathogenesis of AIS, implying that CDC42 might be implicated in the development of AIS (6, 8, 24). Additionally, an in vitro study reported that the activation of CDC42 promoted the migration of endogenous neural stem/progenitors cells after ischemic stroke, which facilitates the recovery of injured brain tissue (25). However, the detailed clinical role of CDC42 in patients with AIS remains unanswered.

In this study, the expression of CDC42 was detected in patients with AIS during a 3-year follow-up period with the aim of evaluating the longitudinal changes of CDC42 and its correlation with disease severity, Th1/2/17 cells, and the prognosis in patients with AIS.

More at link.

 

Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients

 What good did this research do in getting survivors recovered? Predictions of recovery failure DO ABSOLUTELY NOTHING!

Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients

Huijuan Jin1, Rentang Bi1, Jichuan Hu2, Da Xu1, Ying Su1, Ming Huang3, Qiwei Peng1, Zhifang Li1, Shengcai Chen1* and Bo Hu1*
  • 1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2Department of Neurology, People's Hospital of Dongxihu District, Wuhan, China
  • 3Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, Wuhan, China

Background and Purpose: Currently, acute ischemic stroke (AIS) is one of the most common and serious diseases in the world and is associated with very high mortality and morbidity even after thrombolysis therapy. This study aims to research the relationship between lactic dehydrogenase (LDH) and prognosis in AIS patients treated with intravenous rtPA.

Method: This study (a Multicenter Clinical Trial of Revascularization Treatment for Acute Ischemic Stroke, TRAIS) included 527 AIS patients in 5 cooperative medical institutions in China from January 2018 to February 2021. The primary outcome was major disability and death within 3 months (mRS score of 3–6), and the secondary outcomes were early neurological improvement (ENI), early neurological deterioration (END), moderate-severe cerebral edema (CE), and symptomatic intracranial hemorrhage (sICH).

Results: The mean age of the 527 patients was 65.6 ± 11.7 years, and the median baseline NIHSS score was 4 (interquartile range, 2–7). The median serum LDH level was 184 U/L (interquartile range, 163–212 U/L). In total, 287 (54.5%) patients acquired ENI, 68 (13.0%) patients suffered END, 53 (12.1%) patients were observed with moderate-severe CE, and 28 (6.2%) patients showed sICH. Within 3 months, 127 (25.15%) patients experienced the primary outcome and 42 (8.3%) patients died. Serum LDH levels before thrombolysis showed an independent association with the risk of primary outcome [adjusted odds ratio, 3.787; (95% CI, 1.525–9.404); P = 0.014]. When log-transformed LDH increased each standard deviation, the risk of primary outcome was raised by 80.1% (95% CI, 28.9–251.7%). A positive linear dependence between the risk of primary outcome and serum LDH levels (P of linearity = 0.0248, P of non-linearity = 0.8284) was shown in multivariable-adjusted spline regression models. Pre-thrombolysis LDH quartile also provided a conventional risk model and significant improvement of the prediction for clinical outcomes, with a net reclassification improvement index (NRI) = 41.86% (P < 0.001) and integrated discrimination improvement (IDI) = 4.68% (P < 0.001).

Conclusions: Elevated serum LDH levels predicted unfavorable clinical outcomes after intravenous thrombolysis in AIS patients.

Introduction

Acute ischemic stroke (AIS) is currently one of the most disabling and lethal diseases in the world (1). Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) as well as endovascular therapy is the most effective primary modality of therapy (2, 3). However, a significant number of patients who receive intravenous rt-PA therapy still face the threat of complications such as hemorrhage transformation and cerebral edema (CE), with unfavorable recovery of neurological function (3, 4). Therefore, it is significant to explore novel prognostic biomarkers in AIS patients for clinical decision making.

Lactate dehydrogenase (LDH) is a critical enzyme of the anaerobic metabolic pathway and is mainly distributed in the cytoplasm and mitochondria of various tissues, including the brain, heart, liver, and lung under physiological conditions (5, 6). Once the tissue is injured, LDH is released to the extracellular space and leads to an increased serum LDH level. Thus, LDH has been regarded as a biomarker of both tissue injury and prognosis in many diseases, including acute myocardial infarction, acute hepatitis, and acute lung injury (710). Presumably, LDH gets rapidly upregulated in brain parenchyma in response to ischemia and hypoxia after AIS, and leaks into circulating blood with the aggravation of cerebral infarction and peripheral edema. LDH has been observed to be released from brain tissue in animal models of brain injury, including ischemic stroke, and has been applied as a marker of brain tissue injury in basial experiments (1113). Clinically, LDH is found to be elevated in the serum and cerebrospinal fluid of patients with ischemic stroke and related to the occurrence of stroke (14).

The relationship between LDH levels and clinical outcomes in AIS patients has never been thoroughly studied (15, 16). This study aimed to analyze the correlation between serum LDH and clinical outcomes in patients receiving intravenous rt-PA treatment.

 

Monday, September 13, 2021

Upper Limb Performance in Daily Life Approaches Plateau Around Three to Six Weeks Post-stroke

 Plateau is a failure of your doctors and therapists, not you. Don't allow that word to be uttered in your presence. I would start screaming at them asking how long they have known of these plateaus and done nothing. You can't let incompetence interfere with your recovery, although you are screwed, but if your doctors and therapists start right now they might have solutions for your children and grandchildren's stroke. Up to you, let sleeping dogs lie or get stroke solved.

Upper Limb Performance in Daily Life Approaches Plateau Around Three to Six Weeks Post-stroke

 
First Published September 12, 2021 Research Article 

Background. 

Wearable sensors allow for direct measurement of upper limb (UL) performance in daily life.  

Objective. 

To map the trajectory of UL performance and its relationships to other factors post-stroke.  

Methods

Participants (n = 67) with first stroke and UL paresis were assessed at 2, 4, 6, 8, 12, 16, 20, and 24 weeks after stroke. Assessments captured UL impairment (Fugl-Meyer), capacity for activity (Action Research Arm Test), and performance of activity in daily life (accelerometer variables of use ratio and hours of paretic limb activity), along with other potential modifying factors. We modeled individual trajectories of change for each measurement level and the moderating effects on UL performance trajectories.  

Results. 

Individual trajectories were best fit with a 3-parameter logistic model, capturing the rapid growth early after stroke within the longer data collection period. Plateaus (90% of asymptote) in impairment (bootstrap mean ± SE: 32 ± 4 days post-stroke) preceded those in capacity (41 ± 4 days). Plateau in performance, as measured by the use ratio (24 ± 5 days), tended to precede plateaus in impairment and capacity. Plateau in performance, as measured by hours of paretic activity (41 ± 6 days), occurred at a similar time to that of capacity and slightly lagged impairment. Modifiers of performance trajectories were capacity, concordance, UL rehabilitation, depressive symptomatology, and cognition.  

Conclusions. 

Upper limb performance in daily life approached plateau 3 to 6 weeks post-stroke. Individuals with stroke started to achieve a stable pattern of UL use in daily life early, often before neurological impairments and functional capacity started to stabilize.

Challenges of Estimating Accurate Prevalence of Arm Weakness Early After Stroke

Useless. Not a single survivor wants to know about failures to recover. They want recovery protocols.  Who approved this piece of useless research?

Challenges of Estimating Accurate Prevalence of Arm Weakness Early After Stroke

First Published July 28, 2021 Research Article Find in PubMed 

Background. 

Recent studies have reported lower statistics of upper limb (UL) weakness (48-57%) compared to widely cited values collected over 2 decades ago (70-80%). Objective. To explore potential factors contributing to the accuracy of prevalence values of UL weakness using a case study from a single regional centre.  

Methods

All patients admitted to the acute stroke unit with suspected diagnosis of stroke were screened from February 2016 to August 2017. Upper limb weakness was captured (a) prospectively using the Shoulder Abduction and Finger Extension (SAFE) score performed by unit physical therapists within 7 days post-stroke and (b) retrospectively via chart review using the National Institutes of Health Stroke Scale (NIHSS) arm score at admission and 24 hours post-admission.  

Results

A total of 656 patients were admitted with a first-ever stroke, and 621 (95%) individuals were administered the SAFE score. A total of 40% of individuals had UL weakness using the SAFE score (SAFE ≤8) at a mean time of 1.9 (SD 1.5) days post-stroke. In the same sample, 57% and 49% had UL weakness using the admission and 24-hour post-admission NIHSS arm score, respectively.  

Conclusions

The accuracy of population-level UL weakness prevalence values can be affected by weakness measure and score cut-off, time post-stroke weakness is captured, sample characteristics and use of single or multiple sites. Researchers using prevalence values for clinical trial planning should consider these attributes when using prevalence data for estimating recruitment rates and resource needs.

The most frequently cited statistic for the prevalence of upper limb (UL) weakness in acute stroke is approximately 70%, provided by data from the Copenhagen Stroke Study (n = 421) collected in 1991/92.1 Other studies from this era have provided even higher prevalence of UL weakness that ranged from 73-77%.2-4 It is possible that the overall prevalence and profile of UL weakness has changed since the above data were collected given advancements in the medical management of acute stroke. For instance, one large unselected study of first-ever stroke (n = 642) collected in 2009/10 in Sweden estimated only 48% of their sample had UL motor impairment.5 Screening data collected in 2017/2018 from an ongoing longitudinal study in Switzerland reported only 57% of consecutive patients with ischaemic stroke (n = 845) experienced UL weakness.6 It is interesting to ponder whether these more recent studies reflect a true change in UL weakness/motor impairment prevalence, differences in sample and/or study methods and/or the increasing use of reperfusion therapies. Capturing a true prevalence value is challenging. Selected arm weakness/impairment measure, threshold scores adopted, time of weakness assessment and number of sites data are collected from have the potential to make a large impact on the accuracy of prevalence estimation aiming to capture the true effect of stroke on the UL. Adding to the complexity is that rehabilitation researchers hoping to use prevalence values to inform clinical trial planning may be interested in prevalence studies that align with their population of interest, planned time post-stroke at recruitment and type of institution where their research will take place. The purpose of this study is to explore potential factors contributing to the accuracy of prevalence values of UL weakness using a case study from a single regional centre. Specifically, we used screening data for a prospective longitudinal cohort study to estimate UL weakness prevalence values using two different weakness measures at three different time points post-stroke to highlight the challenges of obtaining true prevalence values and/or values that may inform clinical trial planning.

 

Saturday, November 21, 2020

Stroke victims’ outcomes vary

 

This acceptance of failure to recover is what is so fucking bad about the stroke medical world. There should be zero variance in getting everyone to 100% recovery.  EXCUSES LIKE THIS SHOULD BE IMMEDIATELY SHOT DOWN.

You're using lack of access as the reason for lack of recovery. WRONG, WRONG, WRONG!  Damn it all, it is lack of stroke rehab protocols that is the problem. You're still in the Dark Ages, thinking guidelines are useful. 

Friday, May 22, 2020

Powered Lower Limb Orthoses: Applications In Motor Adaptation and Rehabilitation

Beneficial, positive benefits and 'may' are code words for YOU having to accept the tyranny of low expectations because the stroke medical world isn't even trying to get survivors 100% recovered. Hope you are OK with that complete fucking failure. 

Powered Lower Limb Orthoses: Applications In Motor Adaptation and Rehabilitation

Abstract—

Task-specific practice can be beneficial for motor rehabilitation after neurological injury. Unfortunately, high labor demands have limited its clinical acceptance, especially for gait rehabilitation. A number of research teams around the world are testing large robotic devices for assisting treadmill stepping as a means for reducing therapist labor. We propose that powered lower limb orthoses may also have a role in assisting gait rehabilitation. Powered orthoses could assist task specific practice of gait with the long-term goal of improving patients’ inherent locomotor capabilities. We present data showing that: (1) pneumatically powered lower limb orthoses can provide substantial mechanical assistance to human walking, (2) powered orthoses can lead to motor adaptation of gait in healthy subjects, and (3) powered lower limb orthoses may have positive benefits(NOT GOOD ENOUGH,we need EXACT PROTOCOLS delivering results.) during gait rehabilitation.
I. INTRODUCTION Locomotor training can improve human walking ability following neurological injury [1-5]. Typically locomotor training involves patients practicing stepping with bodyweight support and external assistance as needed [6]. This therapy was developed based on two major principles learned from extensive studies on cats [7-11] and rats [12]. The first principle, task specificity (as applied to locomotor training), states that to improve walking ability patients must practice walking [11]. The second principle, activity dependent plasticity, states that patients must be active participants in the therapy to drive neural adaptation [13, 14]. The functional benefits of locomotor training with manual assistance are considerable but so are the costs. Providing proper manual assistance is physically demanding and requires a high level of skill and training.  Because it is labor intensive, a session of locomotor training with manual assistance can require several therapists. In addition the skill of the therapist is a very important factor in determining the
Manuscript received April 4, 2005. This work was supported in part by Christopher Reeve Paralysis Foundation FAC2-0101, NIH R01NS045486 and NSF BES-0347479.  1Gregory S. Sawicki is with the Division of Kinesiology and Department of Mechanical Engineering at the University of Michigan, Ann Arbor, MI 48109-2214, USA ( e-mail: gsawicki@ umich.edu). 2Keith Gordon is with the Division of Kinesiology at the University of Michigan, Ann Arbor, MI 48109-2214, USA (e-mail: kegordon@umich.edu). 3Corresponding Author: Daniel P. Ferris is with the Division of Kinesiology and Department of Biomedical Engineering at the University of Michigan, Ann Arbor, MI 48109-2214, USA (phone: 734-647-6878; fax: 936-1925; e-mail: ferrisdp@umich.edu).
efficacy of the therapy. Because of the drawbacks to manual locomotor training, scientists and engineers are developing robotic devices that can assist gait rehabilitation. Most of the currently available devices are designed to guide the legs through preprogrammed physiological gait patterns. The Lokomat® System developed by Hocoma (Switzerland) consists of a position controlled robotic gait orthosis that attaches to a treadmill frame and a body weight support system [15-18]. The AutoAmbulator® [www.autoambulator.com] is a similar device being developed by HealthSouth, a commercial healthcare provider. The Mechanized Gait Trainer is based on a crank and rocker gear system, providing limb motion similar to that of an elliptical trainer [19, 20]. Reinkensmeyer et al. are also working on devices that use pneumatic actuators and high bandwidth force control [21, 22]. All of these robotic devices clearly have potential for assisting gait rehabilitation after neurological injury, especially for patients with little to no walking ability. However, for patients with some but limited walking ability, it may also be helpful to consider other complementary devices.  An alternative approach for robotic gait rehabilitation devices is to make them wearable so that they can function during overground locomotion. This would allow the practice of task specific aspects of walking such as gait initiation and termination, turning, negotiating slopes, dynamic balance control and speed modulation. In addition, it may prove particularly helpful to provide powered plantar flexion during gait practice. In healthy subjects, the ankle joint contributes more mechanical work to the gait cycle than either the hip or the knee [23]. A powered lower limb orthosis could mechanically assist at the ankle joint while allowing subjects more freedom in their gait pattern during rehabilitation. A powered orthosis might be especially useful for patients who are ready to practice more demanding locomotor tasks like turning and obstacle avoidance. Although lower limb orthoses have traditionally been passive, there have been attempts at providing powered versions. Importantly, the main goal of these previous prototypes has been to create assistive technology. These research teams envisioned replacing lost motor capabilities rather than improving motor capabilities through therapy. In the 1970s, Vukobratovic built pneumatic robotic exoskeletons for human walking [24, 25]. Seireg et al. developed a hydraulic device with a dual axis hip, dual axis ankles, and a single axis knee joint [26]. A more recent
attempt was the Powered Gait Orthosis (PGO), a four bar linkage and CAM system [27]. Blaya et al. built an orthosis to assist drop foot gait [28]. In addition, there are other groups developing powered lower limb orthoses to replace lost motor function of patients [29, 30]. All of these prototypes have had difficulty with achieving sufficient energy density. That is, to make the devices truly portable so they can function as assistive technology, the actuators and batteries have to be powerful and lightweight while providing many hours of use. Powered orthoses for motor rehabilitation do not face as many technical difficulties as those intended for use as assistive technology. Using a powered lower limb orthosis as gait therapy would restrict the device to the clinic. As a result, control hardware and power do not have to be on board the orthosis itself. Electric, hydraulic, or pneumatic energy could be supplied through a tether that includes cables connected to a desktop computer. A therapist could have real-time control over the magnitude and timing of mechanical assistance during gait practice. In addition, sensors could provide feedback to the therapist about the performance of the patient. As rehabilitation progresses, the patient could be weaned by decreasing orthosis assistance.  This would enforce active patient participation over the training period. The ultimate goal would be to divorce the patient from the powered orthosis as motor capabilities improved. The following sections describe our initial attempts at developing powered orthoses for motor rehabilitation and discuss alternative uses for the orthoses in studying motor adaptation during human walking.

Saturday, January 25, 2020

Development and validation of a questionnaire to assess barriers to physical activity after stroke: The barriers to physical activity after stroke scale

This is so easy. The answer to every barrier is that your stroke medical professionals failed completely in getting you to 100% recovery. 

Development and validation of a questionnaire to assess barriers to physical activity after stroke: The barriers to physical activity after stroke scale

Archives of Physical Medicine and Rehabilitation , Volume 100(9) , Pgs. 1672-1679.

NARIC Accession Number: J82450.  What's this?
ISSN: 0003-9993.
Author(s): Drigny, Joffrey; Joussain, Charles; Gremeaux, Vincent; Morello, Remy; Van Truc, Patricg h.; Staple, Paul; Touze, Emmanuel; Ruet, Alexis.
Publication Year: 2019.
Number of Pages: 8.

Abstract: 

Article describes the development and validation of a self-reported questionnaire assessing the barriers to physical activity (PA) among stroke survivors. One hundred forty-six individuals were included in this study. In stage 1, semi-structured interviews conducted with 37 community-living stroke survivors with low-moderate disability identified perceived barriers to PA, which were then selected by the expert panel and grouped on a Barriers to Physical Activity After Stroke (BAPAS) scale. In stage 2, 109 stroke participants (40 were women) with same characteristics completed a personal information questionnaire and the BAPAS scale. Nine professionals experienced in PA for poststroke patients formed an expert panel. An item selection process with factor analysis was carried out. The suitability of the data set was analyzed using the Kaiser-Meyer-Olkin coefficient, internal consistency was evaluated by Cronbach alpha, and concurrent validity was assessed with Spearman correlation coefficients between the BAPAS scale and the modified Rankin Scale. Test-retest repeatability was estimated using 2-way random effects intraclass correlation coefficient model at 4- to 6-day follow-up. Factor analysis supported a 14-item BAPAS that explained 62 percent of total variance and total score calculated higher than 70 (higher scores for higher barriers). Cronbach alpha was 0.86, Spearman correlation with the modified Rankin Scale was 0.65, and test-retest intraclass correlation coefficient was 0.91. The BAPAS scores were higher in patients with greater disabilities and in those with a longer time since the stroke event. This study developed and validated the BAPAS scale to assess barriers to PA in stroke survivors with low-moderate disability with promising psychometric properties.
Descriptor Terms: BARRIERS, EXERCISE, MEASUREMENTS, OUTCOMES, PERFORMANCE STANDARDS, STROKE.


Can this document be ordered through NARIC's document delivery service*?: Y.

Citation: Drigny, Joffrey, Joussain, Charles, Gremeaux, Vincent, Morello, Remy, Van Truc, Patricg h., Staple, Paul, Touze, Emmanuel, Ruet, Alexis. (2019). Development and validation of a questionnaire to assess barriers to physical activity after stroke: The barriers to physical activity after stroke scale.  Archives of Physical Medicine and Rehabilitation , 100(9), Pgs. 1672-1679. Retrieved 1/25/2020, from REHABDATA database.

Tuesday, October 1, 2019

Folding paper failure

I needed to get a medallion signature guarantee when trying to redeem a mutual fund and mail it back. For me to fold it into thirds to fit inside a business envelope is impossible with any sort of neatness. So I punted and asked the staff person at the bank to do it for me, she also inserted it into the envelope which I mostly can do after 10 minutes or so. Another failure in getting me recovered and doing ADLs.